SCHEDULE 13G/A: Matrix Capital Management Reports Full Divestment of Adaptimmune Therapeutics Stake

Matrix Capital Management Company LP and David E. Goel have filed an amended Schedule 13G, indicating they no longer beneficially own any shares of Adaptimmune Therapeutics plc as of December 31, 2024.

Summary

• This document is Amendment No. 9 to a Schedule 13G filing by Matrix Capital Management Company LP and David E. Goel.
• The filing pertains to their beneficial ownership of Ordinary Shares (represented by American Depository Shares, ADSs) of Adaptimmune Therapeutics plc (CUSIP 00653A107).
• As of the event date of December 31, 2024, both Matrix Capital Management Company LP and David E. Goel report 0% beneficial ownership of the class of securities.
• This indicates a complete divestment of their previously held stake or a reduction below the reporting threshold.
• The reporting persons certify that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 3

Explanation: The filing indicates a complete divestment by a significant institutional investor, which can be perceived negatively by the market as it suggests a lack of confidence or a strategic shift away from the company.

Negatives

• Matrix Capital Management Company LP and David E. Goel have reduced their beneficial ownership in Adaptimmune Therapeutics plc to 0%, indicating a complete divestment or reduction below the reporting threshold, which may signal a lack of investor confidence.

Stakeholder Impact

• Shareholders may react negatively to the news of a significant institutional investor divesting its entire stake, potentially leading to a decrease in share price.

Key Dates

Recommendation

Keywords

Adaptimmune Therapeutics, Matrix Capital Management, Schedule 13G, SEC filing, beneficial ownership, divestment, ordinary shares, ADSs